Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP13448.RAyhbSXCXvdZLBbHzI56fufaVBaB8Thg0TXaMY6sYoYeI130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP13448.RAyhbSXCXvdZLBbHzI56fufaVBaB8Thg0TXaMY6sYoYeI130_provenance.
• NP190608.RAdbDhYk-4YqsFW3TG-e0wqlib3hRkN6sIxg2qhWyXqTc130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP190608.RAdbDhYk-4YqsFW3TG-e0wqlib3hRkN6sIxg2qhWyXqTc130_provenance.
• NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_provenance.
• NP55033.RAaSVeiUo7_7LD79JsOM_YsgIku1rLdpjCuEE5F9bB2x4130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP55033.RAaSVeiUo7_7LD79JsOM_YsgIku1rLdpjCuEE5F9bB2x4130_provenance.
• assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
• NP341632.RAb4TnYzhA7PKlcfNFox2VDtFENdMBJen0MoTy10QUuFA130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341632.RAb4TnYzhA7PKlcfNFox2VDtFENdMBJen0MoTy10QUuFA130_provenance.
• NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_provenance.
• NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_provenance.
• NP451652.RAwoCn1BGBr4dtdZEyvsxCYVZTdDCh4oBbsOlp0tOcyOM130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451652.RAwoCn1BGBr4dtdZEyvsxCYVZTdDCh4oBbsOlp0tOcyOM130_provenance.
• NP86701.RA_DEJ3b0lJ01IeTRt5FG1bBFUbGrlR8w5DiQlBSDnWxs130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP86701.RA_DEJ3b0lJ01IeTRt5FG1bBFUbGrlR8w5DiQlBSDnWxs130_provenance.